A Mount Sinai study reports that one amino-acid change alters Andes virus glycoprotein movement and virus-like particle release in human cells.
A precise change in a viral protein
Researchers at the Icahn School of Medicine at Mount Sinai reported on November 6 that a single amino-acid difference can change how an Andes virus glycoprotein behaves inside human cells. The finding was published in Science Advances. It helps explain differences between closely related viral isolates, but it does not establish why the virus can sometimes spread between people. That distinction is critical because laboratory results can easily be overstated when they involve a serious infectious disease. The study identifies a mechanism worth investigating, not a new diagnostic test, treatment or proof of increased transmissibility.
What makes Andes virus unusual
Andes virus is a rodent-borne hantavirus associated with severe hantavirus pulmonary syndrome. Unlike most known hantaviruses, Andes virus has been associated with person-to-person transmission. That feature makes its biology especially important to understand, but the ability of a virus to spread depends on many interacting factors. A laboratory experiment involving one protein cannot capture the full chain of events from infection to transmission. The researchers’ work focuses on how viral components are processed inside cells, a narrower and scientifically tractable question. Understanding that step may eventually help explain larger biological patterns, but the connections require further evidence.
Comparing isolates from different hosts
The Mount Sinai team compared a rodent-derived Andes virus isolate with a human-derived isolate collected during the 2018–2019 outbreak in Epuyén, Argentina. That outbreak involved person-to-person transmission and caused 11 deaths, according to the institution’s report. Earlier research had suggested that the genetically similar isolates behaved differently. Comparing closely related samples can help researchers narrow the list of changes that might matter. It does not prove that a difference arose because of adaptation to humans. The isolates may vary for several reasons, and any proposed causal mechanism must be tested directly.
Twenty-five differences and one focus
Researchers identified 25 amino-acid differences between the two isolates. They focused on a particular change near the glycoprotein cleavage domain, a region relevant to how viral proteins are processed and assembled. Amino acids are the building blocks of proteins, and changing one can alter a protein’s shape, stability or interactions with cellular machinery. But most individual substitutions do not automatically produce a dramatic biological effect. The significance of this experiment lies in testing a specific candidate change and observing a measurable difference. It is not evidence that every mutation near the same domain will behave in a similar way.
Looking beyond RNA production
The rodent-derived isolate grew faster in the team’s comparison, although both isolates eventually reached similar levels. Researchers did not find a major change in viral RNA production sufficient to explain the difference, so they examined later stages of the viral lifecycle. That reasoning is important because viral replication involves several distinct steps. A change in the rate at which viral components leave a cell may arise even when RNA synthesis is similar. Separating those stages allows investigators to ask more precise questions. It also prevents a misleading conclusion that faster particle release must mean faster genome replication.
The Golgi apparatus connection
The team altered one amino acid in the human-derived isolate’s glycoprotein to match the rodent-derived version. The modified protein spent less time in the Golgi apparatus, a cellular compartment that helps process and transport proteins. Virus-like particles were then released more quickly. The observation provides a plausible link between a specific protein sequence and a particular cellular process. It does not, by itself, reveal every intermediate step or establish how the complete infectious virus would behave in a human body. Protein trafficking is influenced by multiple cellular interactions, and the experimental system captures only part of that complexity.
Why virus-like particles are used
The investigators used molecular expression systems and virus-like particles rather than genetically modified infectious Andes virus. Such systems can reproduce selected aspects of viral assembly and release without requiring a complete infectious virus. They are valuable for investigating mechanisms under controlled conditions. Their safety and experimental advantages also create interpretive limits: a particle lacking the full viral lifecycle cannot demonstrate all the behaviours of an infectious pathogen. The study’s authors explicitly caution that the observed amino-acid effect does not establish person-to-person transmission or adaptation to humans. Any reporting that makes those claims would go beyond the evidence.
A finding about cell biology
The result adds detail to researchers’ understanding of how glycoprotein processing may affect viral particle release. The Golgi apparatus is a central hub for modifying and sorting many proteins, including those used by viruses. A protein’s time spent in that compartment can influence where and when it becomes available for assembly. Studying those steps may reveal biological vulnerabilities or clarify why related viral isolates behave differently. However, identifying a cellular mechanism is several steps removed from developing a medicine. Researchers would need to establish whether the mechanism matters in infection and whether it can be targeted safely.
Why transmission cannot be inferred
Transmission between people requires a sequence of events: a virus must infect a host, replicate, leave the body in a viable form and reach another susceptible person. The laboratory result concerns intracellular protein behaviour and virus-like particle release. It does not measure all of those events. The distinction matters because sensational descriptions of a ‘human-adapted mutation’ could create unnecessary alarm. The Mount Sinai report specifically says more research is needed to determine the change’s effect in the complete virus and any relationship to disease or transmission. Caution is not a weakness of the study; it is part of its scientific credibility.
How the research may guide future work
The findings provide a focused hypothesis for further experiments. Researchers could investigate which cellular interactions are altered by the amino-acid substitution and whether similar effects appear in other relevant experimental systems. They may also examine additional sequence differences to understand how multiple changes interact. Such work would need appropriate biosafety oversight and careful interpretation. The November announcement does not describe a validated clinical intervention or recommend changes to public health guidance. Its value is in reducing uncertainty about one part of the virus’s biology and identifying questions that can be tested systematically.
Reading outbreak history responsibly
The institution noted the fatal 2018–2019 Epuyén outbreak and referenced a 2026 outbreak aboard the cruise ship Hondius. These events provide context for why Andes virus is studied, but the laboratory experiment did not determine the cause of either outbreak. Historical associations must not be turned into causal claims about the particular amino-acid difference. Public health investigations consider epidemiological evidence, exposure patterns and laboratory results together. The appropriate message for readers is that a serious pathogen is being studied with increasingly precise tools, not that researchers have discovered a single switch controlling its spread.
What the study changes
The new work identifies a specific protein-sequence difference that affects trafficking and virus-like particle release in a human-cell experimental system. That is a meaningful contribution because it links a molecular variation to an observable process. Its limits are equally important: the work does not establish increased human transmissibility, predict a new outbreak or provide a treatment. Future studies will need to connect the laboratory observation with the biology of complete infection. For now, the result is a carefully bounded advance in understanding a virus whose behaviour has significant public health implications.
Frequently asked questions
What did Mount Sinai researchers discover?
They found that a single amino-acid substitution changes Andes virus glycoprotein trafficking and speeds release of virus-like particles in a laboratory system.
Does the change make Andes virus more contagious?
The study did not establish that. Researchers said further work is needed to determine any relationship to infection or person-to-person transmission.
Did the team engineer infectious Andes virus?
The reported experiments used expression systems and virus-like particles rather than genetically modified infectious Andes virus.
